Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...

In studies of Ozempic for type 2 diabetes, 20.3% of participants taking a 1-milligram (mg) dose of Ozempic reported feeling nauseous, compared to 6.1% of those given a placebo. Higher doses are ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

the dose may be increased to 1 mg once weekly. In some cases, healthcare providers may prescribe up to 2 mg once weekly. Ozempic should be injected subcutaneously in the abdomen, thigh ...

Novo Nordisk (NVO ... the Danish drugmaker said that Ozempic, also known as semaglutide, at a once-weekly 1.0 mg dosing led to a 13% improvement in maximum walking distance compared to placebo ...